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Leptin and leptin receptor expression in asthma
Andreina Bruno, PhD,a Elisabetta Pace, MD,a Pascal Chanez, MD,b Delphine Gras, PhD,b Isabelle Vachier, PhD,c
Giuseppina Chiappara, PhD,a Maurizio La Guardia, MD,d Stefania Gerbino, PhD,a,d Mirella Profita, PhD,a
and Mark Gjomarkaj, MDa Palermo, Italy, and Marseille and Montpellier, FranceBackground: The adipokine leptin is a potential new mediator
for bronchial epithelial homeostasis. Asthma is a chronic
inflammatory disease characterized by airway remodeling that
might affect disease chronicity and severity. TGF-b is a tissue
growth factor the dysregulation of which is associated with
airway remodeling.
Objective: We sought to determine whether a bronchial
epithelial dysfunction of the leptin/leptin receptor pathway
contributes to asthma pathogenesis and severity.
Methods: We investigated in vitro the presence of leptin/leptin
receptor on human bronchial epithelial cells. Then we studied
the effect of TGF-b and fluticasone propionate on leptin
receptor expression. Finally, the role of leptin on TGF-b release
and cell proliferation was analyzed. Ex vivo we investigated the
presence of leptin/leptin receptor in the epithelium of bronchial
biopsy specimens from subjects with asthma of various
severities and from healthy volunteers, and some features of
airway remodeling, such as reticular basement membrane
(RBM) thickness and TGF-b expression in the epithelium, were
assessed.
Results: In vitro bronchial epithelial cells express leptin/leptin
receptor. TGF-b decreased and fluticasone propionate increased
leptin receptor expression, and leptin decreased the spontaneous
release of TGF-b and increased cell proliferation. Ex vivo the
bronchial epithelium of subjects with mild, uncontrolled,
untreated asthma showed a decrease expression of leptin and its
receptor and an increased RBM thickness and TGF-b
expression when compared with values seen in healthy
volunteers. Furthermore, severe asthma was associated with a
reduced expression of leptin and its receptor and an increased
RBM thickness with unaltered TGF-b expression.
Conclusions: Decreased expression of leptin/leptin receptor
characterizes severe asthma and is associated with airway
remodeling features. (J Allergy Clin Immunol 2009;124:230-7.)
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Leptin, a 16-kd adipocyte-derived hormone originally
described in metabolism regulation, plays a pleiotropic role
in the immune system and inflammation.1 Leptin exerts its
action through the leptin receptor (Ob-R) by activating both
phosphatidylinositol-3-OH kinase and mitogen-activated pro-
tein kinase signaling pathways.2,3 Ob-R belongs to the glyco-
protein 130 family of cytokine class I receptors and is present
in many tissues, including the brain, placenta, hematopoietic
cells, liver, heart, and lung.4 During skin repair,5 leptin might
function as a regulatory link between the endocrine and im-
mune systems and might represent a bridge between inflam-
mation and tissue repair. It also contributes to regulation of
the maturation of fetal lung cells6 and to homeostasis of the
endothelium.7 Leptin is increased during allergic reactions
in the airways and might play a role in the relationship
between obesity and asthma.8 The specific role of the lep-
tin/leptin receptor pathway in the bronchial epithelium from
asthmatic patients is still largely unexplored. In patients
with asthma, there is increasing evidence for an important
role played by the epithelium in orchestrating the inflamma-
tory responses and in producing a chronic wound scenario
involving tissue injury and aberrant repair leading to airway
remodeling.9 Airway remodeling has been related to the
severity of asthma, and consistently, major tissue changes
have been observed in patients with fatal asthma.10 Subepithe-
lial thickening caused by excessive collagen deposition
beneath the reticular basement membrane (RBM) is one of
the most frequent features of airway remodeling in patients
with asthma.11-14 TGF-b, a cytokine overexpressed in patients
with asthma, is considered one of the major fibrogenic factors.
It exists in 3 pleiotropic isoforms that play important roles in
the regulation of inflammation, cell growth, differentiation, and
wound healing. The expression of TGF-b correlates with the de-
gree of subepithelial changes in patients with asthma,15 and its
production is downregulated by corticosteroids.16 Inhaled corti-
costeroids and bronchodilators are the mainstay of treatment in
persistent asthma, but they are relatively less effective in the
treatment of severe asthma.17,18 It has been assessed that syn-
thetic dexamethasone stimulates both leptin synthesis in preadi-
pocytes19 and adipocytes20 and increases leptin secretion and
leptin receptor mRNA expression in choriocarcinoma cells,21
whereas the addition of TGF-b in the presence of dexametha-
sone blocks cell numbers in preadipocytes culture.19
The present study was performed to investigate both in vitro
and ex vivo the role of the leptin/leptin receptor pathway and its
relationship with different aspects of airway remodeling and
regarding various aspects of human asthma, including the
response to corticosteroids.
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BECs: Bronchial epithelial cells from brushings
FP: Fluticasone propionate
C: Healthy control volunteer
ICS: Subject with mild asthma controlled with inhaled
corticosteroids
NHBE: Normal human bronchial epithelial
RBM: Reticular basement membrane
SDA: Subject with severe uncontrolled asthma treated with inhaled
and oral corticosteroids
UA: Subject with mild uncontrolled untreated asthma
METHODS
This study was approved by the local ethics committee, and all patients
provided written informed consent.
Cell cultures
The human bronchial epithelial SV40 immortalized cell line 16HBE 14 o-,22
primary normal human bronchial epithelial (NHBE) cells (Lonza, Brussels,
Belgium), and bronchial epithelial cells (BECs) from bronchial brushings
were investigated. The detailed methods for cell-line cultures and immunocyto-
chemistry are described in the Methods section of this article’s Online
Repository, which is available at www.jacionline.org.
Confocal laser scanning microscopy
Cytospin preparations were created from in vitro differentiated NHBE
cells, and cells were fixed and permeabilized as previously described.2,3
Immunofluorescent staining was performed with the rabbit polyclonal anti-
body Ob anti-leptin (A-20) and the goat-polyclonal antibody Ob-R anti-leptin
receptor against the common part of the short and long isoform (M-18; both
1:40 dilution, overnight at 48C; Santa Cruz Biotechnology, Santa Cruz, Calif).
The primary antibodies were diluted in PBS plus 3% BSA plus 2% normal
serum. Nonimmune IgG at the same titer (0.25 mg/mL) as the primary
antibodies was used as a negative control. Incubation with appropriate tetra-
methylrhodamine isothiocyanate– and fluorescein isothiocyanate–conjugated
secondary antibodies (both from Jackson Immunoresearch, Immunotech,
France) was performed in the dark for 1 hour at room temperature. The anti-
fading agent Slowfade (Molecular Probes, Invitrogen, Carlsbad, Calif) was
added, and slides were analyzed by using a confocal laser scanning micro-
scope (SP5 Confocal; Leica, Wetzlar, Germany) equipped with Ar and
HeNe lasers at a final magnification of 3630.
Flow cytometric analysis for leptin receptor
16HBE cells, NHBE cells, and BECs were analyzed for leptin receptor
expression by using FACS analysis. All the cells were incubated in the
antibody Ob-R for 1 hour at 48C. Nonimmune IgG at the same titer (1 mg/mL)
as the primary antibodywas used as a negative control. Cells were thenwashed
in cold PBS and incubated with fluorescein isothiocyanate–conjugated
polyclonal rabbit anti-goat immunoglobulin (DAKO, Glostrup, Denmark) in
the dark for 30 minutes at 48C. Fluorescence-positive cells were quantified by
using a FACSCalibur (Becton Dickinson, Mountain View, Calif) flow
cytometer. Percentages of positive cells were determined from forward and
sideways scatter patterns. Nonspecific binding and background fluorescence
were quantified by analyzing the negative control.
16HBE cell treatment
16HBE cells were cultured in the presence or absence of recombinant
human TGF-b1 (2 ng/mL) and fluticasone propionate (FP; 1028 M; Glaxo
SmithKline, Greenford, United Kingdom) for evaluating leptin receptor
expression at 24 hours (n 5 6). Furthermore, 16HBE cells were cultured in
the presence or absence of recombinant human leptin (0.5mmol/L) and recom-
binant human TNF-a (30 ng/mL) for TGF-b1 release. Experiments were per-
formed from 3 to 6 times at 24 and 48 hours. Anti–TGF-b1 mAb was used toneutralize the TGF-b1 activity, and the pharmacologic inhibitors SB203580
(inhibitor of p38 mitogen-activated protein kinase) and LY294002 (inhibitor
of phosphatidylinositol-3-OH kinase; both at 50 mmol/L; Sigma, St Louis,
Mo) were used to neutralize the leptin activity.2,3 The cells were cultured
with or without leptin (0.5 mmol/L) for evaluating cell proliferation. All cyto-
kines and antibodies are from R&D Systems (Minneapolis, Minn).
TGF-b1 release by 16HBE cells
Supernatants were recovered, centrifuged, and stored at 2808C until
assayed. TGF-b1 concentrations were measured with a commercially avail-
able ELISA Kit (RD; Amersham-Pharmacia Biotech, Little Chalfont, Bucks,
United Kingdom). The sensitivity of the assay was 4.0 pg/mL.
Clonogenic assay in 16HBE cells
The colony growth of 16HBE cells exposed to leptin for 24 hours was
assessed. Detailed methods are described in the Methods section of this
article’s online repository.
Ex vivo study
The patients were consecutively recruited and enrolled over a 6-month
period. Four groups of subjects were enrolled in this study: healthy control
volunteers (C; n5 15); subjects withmild uncontrolled untreated asthma (UA;
n 5 8); subjects with mild asthma controlled with inhaled corticosteroids
(ICS; n 5 8), and subjects with severe uncontrolled asthma treated with
inhaled and oral corticosteroids (SDA; n 5 15). Asthmatic subjects were
selected according to the last Global Initiative for Asthma guidelines.23 They
were classified as having uncontrolled asthma according to their recent
Asthma Control Questionnaire score24 and their exacerbation rate during
the last year.25 The clinical severity of asthma was assessed by using the
Global Initiative for Asthma guidelines and based on the anti-inflammatory
treatments used to reach control.18 All patients and healthy volunteers were
nonsmokers. Subjects who had any bronchial or respiratory tract infections
during the month preceding the test were excluded from the study.
Bronchoscopy and tissue processing and staining
Fiberscopic bronchoscopy was performed by the same physician as
previously described.26 The detailed methods for biopsy treatments are
described in the Methods section of this article’s Online Repository.
Statistical analysis
Results are expressed as means 6 SDs. Unpaired t tests for in vitro exper-
iments and Kruskal-Wallis tests for ex vivo evaluations were performed. A
non-parametric Mann Whitney test was then applied between two groups as
the initial Kruskal Wallis test was significant. Correlations were determined
with a Spearman rank correlation test. A P value of less than .05 was consid-
ered statistically significant.
RESULTS
Bronchial epithelial cells express leptin/leptin
receptor
NHBE cells, BECs, and 16HBE cells constitutively express
leptin and leptin receptor by means of immunofluorescence
(NHBE cells) and immunocytochemistry (NHBE cells, BECs,
and 16HBE cells). The results are representative of 3 experiments
in each cell line (Fig 1).
Flow cytometric analysis for leptin receptor
16HBE cells, NHBE cells, and BECs express leptin receptor
(Fig 2) by means of FACS analysis. Furthermore, on 16HBE
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232 BRUNO ET ALFIG 1. Immunofluorescence fromNHBE cells for leptin (A) and leptin receptor (B). Particulars are shown in C
and D. The expression of leptin receptor appears more apical than basolateral (magnification 3630). Bar 5
10 mm. Negative controls are shown in E through H. Immunocytochemistry for leptin (I) and leptin receptor
(J) from 16HBE cells (red), NHBE cells (K and L), and BECs (M and N; brown) is also shown (magnification at
31000). Insets show negative controls.
FIG 2. Flow cytometric analysis for leptin receptor expression in 16HBE cells (A), NHBE cells (B), and BECs
(C). Physical parameters (left) and overlay of fluorescence intensity (FL1; right) related to the expression of
leptin receptor versus events histogram of cells cultured inmedium.White peaks indicate negative controls.
SSC-H, Side light scatter-height; FSC-H, forward light scatter-height.
J ALLERGY CLIN IMMUNOL
VOLUME 124, NUMBER 2
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expression in 16HBE cells cultured with medium, TGF-b1, FP, and anti–TGF-b1. B, Supernatants from 16HBE
cells stimulated with leptin, leptin pharmacologic inhibitors, and TNF-a were assessed for TGF-b1 release
(ELISA). C, 16HBE colony numbers on leptin incubation. *P < .05, unpaired t test.cells, TGF-b1 significantly decreased (P < .01) whereas FP
significantly increased (P < .0005) the constitutive leptin re-
ceptor expression (Fig 3, A). The anti–TGF-b1 neutralizing
mAb completely abrogated the TGF-b1 activity (P < .007;
Fig 3, A).
Leptin decreases TGF-b1 release and increases cell
proliferation
On 16HBE cells, leptin and TNF-a were able to significantly
decrease the spontaneous release of TGF-b1 both alone (P < .01
and P < .02, respectively) and combined (P < .001) at both 24
(Fig 3, B) and 48 (data not shown) hours. The pharmacologic
inhibitors SB203580 and LY294002 completely abrogated the
leptin activity (P < .03; Fig 3, B). Leptin was able to significantly
increase (P < .001) the colony number (Fig 3, C).Subjects
The demographic characteristics and pulmonary functions of
the 4 studied groups are reported in Table I.
Leptin/leptin receptor and TGF-b expression in
bronchial epithelium
In the bronchial epithelium the expression of leptin (Table II
and Fig 4) and its receptor (Table II and Fig 5) was assessed.
The expression of both leptin and its receptor was significantly
lower in UAs (P < .001 and P < .01) and SDAs (P < .001 and
P < .001) than in C, whereas it was significantly higher in ICS
than UA (P < .03 and P < .01) and SDA (P < .01 and P < .01).
Differently, the expression of TGF-b was significantly higher in
UAs than in the other 3 groups (P < .01, P < .05, and P < .03, re-
spectively; Table II and Fig 6).
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C UA ICS SDA
No. 15 8 8 15
Age (y) 29.5 (25-34) 21 (20-52) 46 (30-51) 53 (44-61)
Sex (M/F ratio) 62% 63% 46% 63%
BMI (kg/m2) 22.50 (22.14-23.70) 23.82 (22.58-27.17) 24.00 (21.11-25.15) 23.63 (20.77-27.96)
FEV1 (% predicted) 108.5 (103-113.5) 60 (53.7-66) 100 (97-111.5) 50 (40-75.5)
ACQ* NA 1.5>/<2 <1 >2
Exacerbations in last
year
NA 1 0 1/2
Oral prednisone
dose (mg/d)
0 0 0 30 (21.2-37.5)
Allergy (%) 0 81.8 77.7 63.6
Data are presented as medians and 25th-75th percentiles.
NA, Not applicable.
*Asthma Control Questionnaire Juniper scores.
Number of exacerbations.TABLE II. Epithelial markers and RBM thickness
C (n 5 15) UA (n 5 8) ICS (n 5 8) SDA (n 5 15)
P value,
C vs
UA
P value,
C vs
ICS
P value,
C vs
SDA
P value,
ICS vs
UA
P value,
ICS vs
SDA
P value,
UA vs
SDA
Leptin
(1 cells/mm2)
5,300
(4,031-7,514)
2,750
(1,545-3,000)
5,722
(3,547-6,761)
2,372
(867-3,714)
<.001 NS <.001 <.03 <.01 NS
Leptin receptor
(1 cells/mm2)
5,532
(4,209-15,542)
3,614
(3,169-3,967)
8,098
(5,949-9,996)
3,236
(2,509-3,956)
<.01 NS <.001 <.01 <.01 NS
TGF-b1
(1 cells/mm2)
2,467
(2,025-2,800)
4,265
(3,778-5,760)
2,065
(1,094-4,230)
2,333
(1,281-3,353)
<.01 NS NS <.05 NS <.03
RBM (mm) 2.24
(1.92-2.89)
6.44
(5.89-7.47)
4.05
(3.2-4.87)
5.79
(4.36-7.12)
<.01 <.04 <.001 NS NS NS
Data are presented as medians and 25th-75th percentiles. Significance between 2 studied groups was assessed by using the nonparametric Mann-Whitney test.Assessment of RBM thickness
RBM thickness was significantly higher in UA, ICS, and SDA
than in C (Table II and see Fig E1 in this article’s Online Repos-
itory at www.jacionline.org).
Correlation analyses
A positive correlation (r5 0.64, P < .001) was found between
leptin and leptin receptor expression, whereas leptin (r520.55,
P < .001) and leptin receptor (r 520.53, P < .001) expressions
were inversely correlated with RBM thickness (see Fig E2 in this
article’s Online Repository at www.jacionline.org). TGF-b
expression was inversely correlated with leptin (r 5 20.48,
P < .02) and leptin receptor expression (r 5 20.6, P < .01)
and positively correlated with RBM thickness (r 5 0.55, P <
.01) only when SDAs were excluded (see Fig E3 in this article’s
Online Repository at www.jacionline.org).
DISCUSSION
In the present study we showed that the leptin/leptin receptor
pathway is involved in the structural changes seen in asthma
through the commitment of the bronchial epithelium. Here we
investigated the contribution of the leptin/leptin receptor pathway
in regulating TGF-b expression on epithelial behavior in vitro and
airway remodeling in subjects with asthma of various severities.First, human bronchial epithelial cells constitutively express lep-
tin and leptin receptor in vitro. Second, the constitutive expression
of leptin receptor is decreased by TGF-b1 and increased by FP in
vitro. Third, leptin decreases the spontaneous release of TGF-
b1 and increases bronchial epithelial cell proliferation through
its receptor. Fourth, leptin/leptin receptor pathway expression in
bronchial epithelium is lower in patients with mild uncontrolled
untreated and severe uncontrolled treated asthma when compared
with the other 2 categories. Fifth, abnormalities linked to airway
remodeling were observed in endobronchial biopsy specimens
from asthmatic subjects. Finally, the lack of leptin/leptin receptor
expression is associated with markers of airway remodeling in pa-
tients with severe asthma.
Leptin might play a key role in asthma remodeling and in
physiologic bronchial epithelial proliferation. Earlier studies sug-
gested that leptin is involved in the pathophysiology of inflamma-
tory processes and immune responses and regulates the epithelial
homeostasis in different compartments.27,28 Asthma is character-
ized by airflow obstruction, airway inflammation, and structural
changes in the airways.29,30 Although information concerning the
genesis of inflammation is abundant, the precise factors responsible
for airway remodeling and for the variable efficacy of corticosteroid
treatment in patients with severe asthma are unknown.
In the bronchi we already reported a reduced expression of
leptin/leptin receptor in epithelial cells of smokers and patients
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Healthy volunteers (C) and subjects with mild uncontrolled (UA), mild controlled (ICS), and severe (SDA)
asthma are shown (magnification at 3400). Scale bar 5 40 mm. B, Leptin expression is significantly lower*
in the UA (P < .001) and SDA (P < .001) groups versus the C group and significantly higher** in the ICS group
vs the UA (P < .03) and SDA (P < .01) groups.
FIG 5. A, Immunohistochemistry for leptin receptor on epithelium from bronchial biopsy specimens
(brown) of healthy volunteers (C) and subjects with mild uncontrolled (UA), mild controlled (ICS), and se-
vere (SDA) asthma (magnification at3400). Scale bar5 40 mm. B, Leptin receptor expression is significantly
lower* in the UA (P < .01) and SDA (P < .001) groups versus the C group and significantly higher** in the ICS
group versus the UA (P < .01) and SDA (P < .01) groups.with chronic obstructive pulmonary disease,4 suggesting a role of
the leptin/leptin receptor pathway in the homeostasis of lung tis-
sue. Airway remodeling is a complex process that involves all the
airway tissue components from the epithelium to the adventitia.
Therefore the question of whether the adipokine leptin is involved
in the functional response to airway remodeling in patients with
severe asthma seems to be of interest. The expression of the
leptin/leptin receptor pathway was first demonstrated in in vitro
differentiated NHBE cells, in BECs, and in the 16HBE cell
line. TGF-b1 significantly reduced and FP significantly increased
the expression of leptin receptor. On the other hand, leptin was
able to significantly reduce TGF-b1 release and to significantly
increase cell proliferation. All these findings demonstrate that
physiologically in the bronchial epithelium, the leptin/leptin
receptor pathway might negatively regulate the overproduction
of TGF-b1, which, in turn, might exert a negative feedback on
leptin receptor expression.
These findings prompted us to investigate the leptin/leptin
receptor and TGF-b expressions in fully differentiated and
polarized epithelium of bronchial biopsy specimens from healthyvolunteers and from subjects with asthma of various severities.
The RBM thickness was also assessed to explore the potential
relationships between airway remodeling and leptin pathway
expressions. Increased subepithelial thickness has been associ-
ated with severe asthma.31
Profibrogenic cytokines, such as TGF-b, promote transdiffer-
entiation of epithelial cells into fibroblasts through a process
called epithelial-mesenchymal transition.32 TGF-b is increased
within the airways in patients with asthma16,33,34 and contributes
to the abnormal activation of the epithelial-mesenchymal trophic
unit,35 a crucial event in airway remodeling. The overproduction
of TGF-b increases the number and activity of subepithelial
myofibroblasts and increases collagen deposition, leading to the
thickening of the subepithelial layer beneath the RBM.36 Leptin
is also important in lung development in the differentiation of lip-
ofibroblasts to normal fibroblasts.37 In this studywe found that the
epithelial expression of both leptin and its receptor is significantly
lower in patients with mild uncontrolled untreated and severe
treated asthma than in patients with mild controlled treated
asthma and healthy volunteers, further supporting a dysregulation
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236 BRUNO ET ALFIG 6. A, Immunohistochemistry for TGF-b on epithelium from bronchial biopsy specimens (red) of healthy
volunteers (C) and subjects with mild uncontrolled (UA), mild controlled (ICS), and severe (SDA) asthma
(magnification at 3400). Scale bar 5 40 mm. B, TGF-b expression is significantly higher* in the UA group
versus the C (P < .01), ICS (P < .05), and SDA (P < .03) groups.of the leptin/leptin receptor pathway linked to asthma control and
bronchial inflammation. The expression of leptin positively corre-
lated with leptin receptor expression, whereas leptin and leptin
receptor expression are inversely correlated with subepithelial
thickness and TGF-b expression. Furthermore, TGF-b expres-
sion is higher in patients with mild uncontrolled untreated asthma
and is positively associated with RBM thickness.
These results confirm previous findings showing that TGF-b
expression is correlated with subepithelial layer thickness,15,38
fibroblast numbers, and disease severity, extending these observa-
tions also to patients with severe asthma in whom changes in the
subepithelial layer are paramount, although their significance
remains speculative.34 Interestingly, in subjects with mild con-
trolled treated asthma the expression of the leptin/leptin receptor
pathway, the expression of the fibrogenic cytokine TGF-b, and
the subepithelial thickness are mostly comparable with what it
is observed in the normal situation. These findings suggest that
the treatment of patients with inhaled corticosteroids and long-
acting b2-agonists might restore some of the structural changes
in certain phenotype of asthma. Differently, in subjects with
severe uncontrolled treated asthma, the persistence of increased
RBM thickness and of reduced leptin/leptin receptor pathway
expression despite the use of high doses of corticosteroids sug-
gests that the lack of this therapy in controlling the disease in
these patients might also be related to the lack of effects in affect-
ing leptin/leptin receptor pathway expression and consequently
RBM thickness. Furthermore, in patients with severe uncon-
trolled treated asthma, we did not find any association between
TGF-b and the leptin/leptin receptor pathway or between TGF-b
and subepithelial layer thickness. Taken together, these findings
strongly support the concept that leptin/leptin receptor pathway
might control the subepithelial layer thickness without the inter-
vention of TGF-b production in severe asthma. Longitudinal
studies might help to better understand the dynamic process
involved in the epithelial changes. The persistent neutrophilic
inflammation associated with a decreased response to corticoste-
roids in patients with severe asthmamight contribute to the persis-
tence of an altered leptin/leptin receptor pathway.
This study contributes to the description of severe asthma as a
condition in which aberrant communication between an injured
airway epithelium and the underlying mesenchyma contributes todisease chronicity and refractoriness to corticosteroids.18 In this
study we found that the leptin/leptin receptor pathway and
TGF-b have the opposite trend of expression in bronchial epithe-
lium according to the control and severity of asthma.
The present study provides evidences of a novel link between
leptin receptor activity and the production of TGF-b in human
bronchial epithelial cells in vitro and in bronchial biopsy speci-
mens from healthy control subjects and asthmatic patients. The
data show that an active leptin signaling pathway is present in
lung epithelial tissue and that its activity is downregulated in
subjects with severe asthma and correlates withmarkers of airway
remodeling. Although recombinant leptin can suppress spontane-
ous release of TGF-b1 in vitro, a feedback mechanism appears to
be in place because exposure of cells to recombinant TGF-b1
causes leptin receptor expression to fall. As a consequence, this
pathway might represent a useful marker to better understand,
follow, and treat patients with severe asthma.
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Key messages
d The leptin/leptin receptor pathway is involved in lung ep-
ithelial homeostasis in asthma.
d Its expression decreases in subjects with uncontrolled and
severe asthma and is inversely correlated with airway
remodeling.
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Cell-line cultures
The human bronchial epithelial SV40 immortalized cell line 16HBE 14 o-
was derived from the epithelium of second-generation bronchi. The 16HBE
cells forming polarizedmonolayers with intact tight junctionswere cultured in
modified Eagle medium plus 10% heat-inactivated (at 568C for 30 minutes)
FBS plus gentamicin solution (25mg per 100mL) plus 1mmol/L L-glutamine
and 25mmol/L HEPES (all from Invitrogen-GIBCO, Grand Island, NY).
Primary NHBE cells (Lonza) were cultured in bronchial epithelial growth
medium (Lonza) by using both a plastic monolayer system and an air/liquid
interface system.E1 Cells were plated on uncoated nucleopore membranes
(24-mm diameter, 0.4-mm pore; Transwell Clear, Cambridge, Mass) in a
1:1 mixture of bronchial epithelial growth medium and Dulbecco modified
Eagle medium (Invitrogen) supplemented with BSA (1.5 mg/mL) and retinoic
acid (50 nmol/L) and applied at the basal side only to establish an air/liquid
interface. Cells were maintained in culture for 21 days to obtain a differenti-
ated cell population with a mucociliary phenotype.
16HBE and NHBE cells were treated with trypsin and then used for further
evaluations.
Bronchial brushings obtained from subjects with no macroscopic bronchial
abnormalities byusing aprotected brush (Olympus,CenterValley, Pa) to sample
bronchial subsegments were placed in RPMI 1640 (10%FBS, 100 U/mL21 and
streptomycin 100 mg/mL) and then vortexed and centrifuged to separate bron-
chial epithelial cells (BECs). The cell viability of BECs was assessed.
Immunocytochemistry
Cytospin preparations were made from 16HBE cells, NHBE cells, and
BECs, and cells were fixed and permeabilized as previously described. After
washing in PBS, slides were incubated with the primary antibodies Ob (1:40
dilution for 1 hour at room temperature) and Ob-R (1:20 dilution overnight at
48C). The reaction was revealed by using the LSAB KIT phosphatase method
for 16HBE cells and by using LSAB1KIT-HRP (all from DAKO) for NHBE
cells and for BECs, according to the manufacturer’s instructions. Nonimmune
IgG at the same titer (0.25 mg/mL for Ob and 1 mg/mL for Ob-R) as the
primary antibodies was used as a negative control. Cytospin preparations were
examined under light microscopy at a final magnification of 31000.
Clonogenic assay in 16HBE cells
In 35-mm Petri dishes (Falcon, Becton Dickinson, Franklin Lakes, NJ) a
lower layer was prepared by using complete modified Eagle medium in 0.5%
agarose. After incubation, cells were harvested and seeded (5 3 104) on the
upper layer with 0.3% agarose prepared with the same medium as the lower
layer and finally incubated for 21 days at 378C in an atmosphere containing0.5% CO2. At the end of incubation, colonies were counted under an inverted
phase-contrast microscope (Leitz, Wetzlar, Germany). The experiment was
conducted in triplicate. Colonies were defined as cell aggregates with at least
40 cells. The true number of colonies was calculated as the number of aggre-
gates on the positive control subtracted from the number of colonies on the ex-
perimental plates. The results are expressed as percentages of the control
value.
Bronchoscopy and tissue processing and staining
Four to 6 bronchial biopsy specimens were taken from each subject by
using the same forceps on a subsegmental bronchus of the lower left lobe.
Endobronchial biopsy specimens were fixed in 10% formaldehyde (pH 7.2)
and embedded in paraffin. Four-micrometer tissue sections were attached to
polylysine-coated microscope slides and, after dewaxing and rehydration,
were stained with hematoxylin or analyzed by means of immunohistochem-
istry. Tissue sections were immunostained with the antibodies Ob (1:50
dilution for 1 hour at room temperature), Ob-R (1:70 dilution for 1 hour at
room temperature), mAb anti–TGF-b1, anti–TGF-b2, and anti–TGF-b3
(MAB1835 40 mg/mL dilution for 1 hour at room temperature; R&D
Systems). Control slides were prepared by using an irrelevant antibody of
the same isotype and at the same concentration as the specific primary
antibodies (0.20 mg/mL for Ob, 0.14 mg/mL for Ob-R, and 1.2 mg/mL for
MAB1835). The immunoreactions were revealed by using the LSAB1KIT-
HRP and APAAP techniques (all from DAKO) for leptin/leptin receptor and
TGF-b expressions, respectively.
Microscopic analysis and RBM thickness
assessment
Biopsy samples were examined with a Leica light microscope. In the
epithelium positive cells for leptin, leptin receptor, and TGF-bwere evaluated
per area over a minimum length of 260 mm from the internal side of the
epithelium, with a final magnification of3400. RBM thickness was expressed
as the average area/length ratio in the valuable region by using the Wilson
method, as previously recommended,E2 with a final magnification of31,250.
The images were subsequently analyzed with Quantimet 500 MC software
(Leica) for image analysis. All biopsy samples were coded, and sections
were analyzed in a blinded fashion by 2 independent investigators.
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BRUNO ET AL 237.e2FIG E1. A, Hematoxylin staining for RBM thickness from bronchial biopsy specimens (blue; magnification
3400). Scale bar 5 40 mm. B, RBM thickness is significantly higher* in subjects with mild uncontrolled
asthma (UA; n 5 8; P < .01), subjects with mild controlled asthma (ICS; n 5 8; P < .04), and subjects with
severe asthma (SDA; n 5 15; P <0.001) versus healthy control volunteers (C; n 5 15).
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237.e3 BRUNO ET ALFIG E2. Correlations between leptin/leptin receptor and RBM. In bronchial epithelium leptin and leptin
receptor expressions are positively correlated with each other (A). Leptin (B) and leptin receptor (C) expres-
sions are inversely correlated with RBM thickness. Healthy volunteers (C; n5 15) and subjects with mild un-
controlled (UA; n 5 8), mild controlled (ICS; n 5 8), and severe (SDA; n 5 15) asthma are shown.
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BRUNO ET AL 237.e4FIG E3. Correlations between leptin/leptin receptor, TGF-b, and RBM. In
bronchial epithelium leptin (A) and leptin receptor (B) expressions are in-
versely correlated with TGF-b expression. TGF-b expression is positively
correlated with RBM thickness (C). Healthy control volunteers (C; n 5 15)
and subjects with mild uncontrolled (UA; n 5 8) and mild controlled (ICS;
n 5 8) asthma are shown.
